X4 Pharmaceuticals (XFOR) Total Current Liabilities (2017 - 2025)

X4 Pharmaceuticals has reported Total Current Liabilities for 9 years, with the latest figure at $25.8 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities fell 21.66% year-over-year to $25.8 million; the trailing twelve-month figure through Dec 2025 stood at $25.8 million (down 21.66% YoY), and the FY2025 full-year result was $25.8 million, down 21.66% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $25.8 million, up from $23.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $32.9 million in Q4 2024, with the low at $13.1 million in Q2 2021.
• Historically, Total Current Liabilities has averaged $22.3 million across 5 years, with a median of $22.9 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 117.0% — and 2025, when it declined 21.66%.
• X4 Pharmaceuticals' Total Current Liabilities stood at $14.0 million in 2021, then jumped by 59.2% to $22.3 million in 2022, then rose by 2.41% to $22.9 million in 2023, then jumped by 43.81% to $32.9 million in 2024, then decreased by 21.66% to $25.8 million in 2025.
• The last three Total Current Liabilities figures came in at $25.8 million (Q4 2025), $23.5 million (Q3 2025), and $22.9 million (Q2 2025), per Business Quant data.